| Literature DB >> 33376564 |
Aleksandra E Szubert-Franczak1, Martyna Naduk-Ostrowska1, Katarzyna Pasicz2, Joanna Podgórska1,3, Witold Skrzyński2, Andrzej Cieszanowski1.
Abstract
The purpose of this article was to show basic principles, acquisition, advantages, disadvantages, and clinical applications of intravoxel incoherent motion (IVIM) magnetic resonance imaging (MRI). IVIM MRI as a method was introduced in the late 1980s, but recently it started attracting more interest thanks to its applications in many fields, particularly in oncology and neuroradiology. This imaging technique has been developed with the objective of obtaining not only a functional analysis of different organs but also different types of lesions. Among many accessible tools in diagnostic imaging, IVIM MRI aroused the interest of many researchers in terms of studying its applicability in the evaluation of abdominal organs and diseases. The major conclusion of this article is that IVIM MRI seems to be a very auspicious method to investigate the human body, and that nowadays the most promising clinical application for IVIM perfusion MRI is oncology. However, due to lack of standardisation of image acquisition and analysis, further studies are needed to validate this method in clinical practice. © Pol J Radiol 2020.Entities:
Keywords: diffusion-weighted imaging; intravoxel incoherent motion; magnetic resonance imaging
Year: 2020 PMID: 33376564 PMCID: PMC7757509 DOI: 10.5114/pjr.2020.101476
Source DB: PubMed Journal: Pol J Radiol ISSN: 1733-134X
Figure 1The intravoxel incoherent motion effect
The b-value used in clinical trials
| Paper | Year | Number of | |
|---|---|---|---|
| Guo [ | 2016 | 0, 10, 20, 30, 50, 70, 100, 150, 200, 400, 800, 1000 | 12 |
| Liu [ | 2013 | 0, 10, 20, 30, 50, 70, 100, 150, 200, 400, 800, 1000 | 12 |
| Ichikawa [ | 2013 | 0, 10, 20, 30, 40, 50, 80, 100, 200, 400, 800, 1000 | 8 |
| Rheinheimer [ | 2012 | [0; 50], [0; 100], [0; 150], [0; 200], [0; 300], [0; 400], [0; 600]; [0; 800] | 8 |
| Cui [ | 2015 | 16 | 16 |
| Dyvorne [ | 2013 | 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 175, 200, 400, 600, 800 | 16 |
| Federau [ | 2014 | 0, 20, 40, 80, 110, 140, 170, 200, 300, 400, 500, 600, 700, 800, 900 | 15 |
| Federau [ | 2014 | 0, 10, 20, 40, 80, 110, 140, 170, 200, 300, 400, 500, 600, 700, 800, 900 | 16 |
| Döpfert [ | 2011 | 0, 50, 500, 800 | |
| Kakite [ | 2016 | 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 175, 200, 400, 600, 800 | 16 |
| Shim [ | 2015 | 0, 10, 20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 300, 500, 700, 900 | 16 |
| Conklin [ | 2016 | 0, 10, 20, 40, 80, 110, 140, 170, 200, 300, 400, 500, 600, 700, 800, 900 | 16 |
| Federau [ | 2016 | 0, 10, 20, 40, 80, 110, 140, 170, 200, 300, 400, 500, 600, 700, 800, 900 | 16 |
| Xu [ | 2016 | 0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 400, 800 | 14 |
| Boss [ | 2016 | 0, 10, 30, 60, 120, 200, 300, 430, 600, 800 | 10 |
| Valerio [ | 2016 | 0, 10, 20, 30, 40, 50, 80, 100, 200, 400, 800 | 11 |
| Pang [ | 2013 | 0, 188, 375, 563, 750 | 5 |
| Bane [ | 2016 | 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 175, 200, 400, 600, 800 | 16 |
Advantages and disadvantages of intravoxel incoherent motion (IVIM) magnetic resonance imaging
| Advantages | Disadvantages |
|---|---|
| Non-invasive technique | Cardiac and respiratory motion artifacts |
| No use of contrast agents | Bulk flow phenomenon artifacts |
| No need of radioisotopes injection | No standardization of acquisition protocols and models |
| No ionizing radiation | Variance in calculated parameters among studies |
| Differential sensitivity to vessel size | |
| Lack of standardization of calculation of IVIM parametres | |
| No established values for normal organs |
Figure 2Sample quantitative maps of intravoxel incoherent motion (IVIM) parameters (D and f, respectively) created using own plugin for ImageJ software for breast cancer liver metastases (arrows). The increase in blood flow/volume occurring in liver metastases can be detected and mapped with IVIM magnetic resonance imaging
Clinical applications of intravoxel incoherent motion magnetic resonance imaging
| Neuroradiology | Oncology | Other |
|---|---|---|
| Cerebral infarction | Brain tumors | Renal function, e.g. renal fibrosis, early changes in diabetic kidneys |
| Brain perfusion | Primary and non-metastatic head and neck tumors | Cardiac imaging |
| Pulsatility of the brain’s microvasculature | Lymph nodal metastasis | Dermatomyositis imaging |
| Pancreatic lesions | Human Achilles tendon imaging | |
| Prostate lesions | Lactating breast lesion imaging | |
| Breast tumors | Orbital lesions imaging | |
| Liver lesions | Vertebral bone marrow imaging | |
| Renal lesions | Thyroid benign and malignant nodule differentiation | |
| Cervical cancer | Tissue characterization of the uterine fibroids | |
| Soft tissue tumors | Ischemic optic neuropathy | |
| Diagnosis of pediatric solid abdominal tumors | Temporomandibular joint disorder imaging | |
| Monitoring treatment efficacy of chemo- or radiotherapy, effectiveness of antiangiogenic drugs and vascular targeting agents | Knee joint in children with juvenile idiopathic arthritis imaging | |
| Invasive fungal infection in the lung treatment response imaging | ||
| Parotid gland imaging in patients with Sjögren diasease | ||
| Placental perfusion imaging |
Figure 3Number of articles about intravoxel incoherent motion magnetic resonance imaging 1987-2018 (PubMed)
Figure 4Number of articles about intravoxel incoherent motion magnetic resonance imaging in oncology 1986-2018 (PubMed)
Characteristics of the included studies
| Autor | Lesion | Parameter | Parameter value | Sensitivity | Specificity | Accuracy | AUC | P value |
|---|---|---|---|---|---|---|---|---|
| Chandarana | Clear cell RCC | ADC × 10-3 mm2/s | 2.2 ± 0.4 | 92.9% | 58.3% | 76.9% | 0.67 | |
| D × 10-3 mm2/s | 1.8 ± 0.6 | 86% | 62.5% | 75.0% | 0.68 | |||
| f | 0.25 ± 0.05 | 100% | 62.5% | 82.7% | 0.74 | |||
| D* × 10-3 mm2/s | 19 ± 13.5 | 0,53 | ||||||
| Cystic RCC and papillary RCC | f | < 0.16 | 100% | |||||
| Clear cell RCC and chromophobe RCC | f | > 0.16 | 100% | |||||
| Ding | Papillary RCC and chromophobe RCC vs. fat poor AML | ADC | > 1.39 | 39.1% | 100% | 60.0% | 0.634 | 0.167 |
| D | > 0.97 | 56.5% | 100% | 71.4% | 0.757 | 0.002 | ||
| D* | ≤ 28.03 | 87.0% | 75% | 82.9% | 0.822 | < 0.001 | ||
| f | ≤ 13.61 | 43.5% | 100% | 62.9% | 0.783 | < 0.001 | ||
| Sumi | Normal parotid gland | D, × 10-3 mm2/s | 0.765 ± 0.138 | |||||
| f | 0.148 ± 0.043 | |||||||
| D*, × 10-3 mm2/s | 41.68 ± 21.91 | |||||||
| Normal submandibular gland | D, × 10-3 mm2/s | 0.999 ± 0.154 | ||||||
| f | 0.133 ± 0.037 | |||||||
| D*, × 10-3 mm2/s | 54.16 ± 23.24 | |||||||
| Malignant salivary gland tumor | D, × 10-3 mm2/s | 0.96 ± 0.22 | ||||||
| f | 0.103 ± 0.0050 | |||||||
| D*, × 10-3 mm2/s | 21.99 ± 19.01 | |||||||
| Pleomorphic adenoma | D, × 10-3 mm2/s | 1.38 ± 0.30 | ||||||
| f | 0.066 ± 0.031 | |||||||
| D*, × 10-3 mm2/s | 10.53 ± 3.48 | |||||||
| Warthin tumor | D, × 10-3 mm2/s | 0.61 ± 0.11 | ||||||
| f | 0.156 ± 0.039 | |||||||
| D*, × 10-3 mm2/s | 42.64 ± 20.17 | |||||||
| Discriminating pleomorphic adenomas from Warthin tumors | D, × 10-3 mm2/s | ≥ 1.1 | 100% | 100% | 100% | |||
| f | ≤ 0.1 | 83% | 100% | 90% | ||||
| D*, × 10-3 mm2/s | ≤ 23 | 100% | 100% | 100% | ||||
| Discriminating malignant salivary gland tumors from benign ones | D, × 10-3 mm2/s | 0.8 < D < 1.1 | 64% | 100% | 87% | |||
| D*, × 10-3 mm2/s | 10 ≤ D*≤ 23 | 73% | 65% | 68% | ||||
| Combined D and D*, × 10-3 mm2/s | 0.8 < D < 1.1, D ≤ 0,8 and D* ≤ 23, or 1.1 ≤ D < 1.4 and D* ≥ 12 | 100% | 100% | 100% | ||||
| Sumi | Lymphomas | PP perfusion-related parameter | 0.09 ± 0.04 | |||||
| D, × 10-3 mm2/s | 0.47 ± 0.07 | |||||||
| Malignant salivary gland tumors | PP | 0.22 ± 0.07 | ||||||
| D, × 10-3 mm2/s | 1.03 ± 0.16 | |||||||
| Squamous cell carcinomas | PP | 0.15 ± 0.04 | ||||||
| D, × 10-3 mm2/s | 0.82 ± 0.17 | |||||||
| Pleomorphic adenomas | PP | 0.13 ± 0.02 | ||||||
| D, × 10-3 mm2/s | 1.44 ± 0.39 | |||||||
| Schwannomas | PP | 0.23 ± 0.08 | ||||||
| D, × 10-3 mm2/s | 1.26 ± 0.20 | |||||||
| Warthin tumors | PP | 0.19 ± 0.04 | ||||||
| D, × 10-3 mm2/s | 0.73 ± 0.22 | |||||||
| Liang L et AL. (42) | Malignant lymph nodes vs benign lymph nodes | D*, × 10-3 mm2/s | 120.89 ± 26.94 vs. 68.78 ± 17.72 | 0.0001 | ||||
| D, × 10-3 mm2/s | 0.57 ± 0.12 vs. 0.74 ± 0.21 | 0.0001 | ||||||
| f (%) | 0.20 ± 0.02 vs. 0.32 ± 0.05 | 0.0001 | ||||||
| ADC, × 10-3 mm2/s | 1.08 ± 0.26 vs. 1.25 ± 0.19 | 0.035 | ||||||
| Federau | Acute ischemic stroke - brain infarct core vs. contralateral side | f | 0.026 ± 0.019 vs. 0.056 ± 0.025 | 2.2 × 10−6 | ||||
| D, mm2/s | 3.9 ± 0.79 × 10-4 vs. 7.5 ± 0.86 × 10-4 | 1.3 × 10-20 | ||||||
| Suo | Ischemic stroke vs contralateral hemisphere | ADC, × 10-3 mm2/s | 0.43 ± 0.10 vs. 0.73 ± 0.07 | < 0.001 | ||||
| D, × 10-3 mm2/s | 0.42 ± 0.10 vs. 0.72 ± 0.07 | < 0.001 | ||||||
| D*, × 10-3 mm2/s | 10.20 ± 4.17 vs. 10.87 ± 4.75 | 0.218 | ||||||
| f (%) | 4.29 ± 2.01 vs. 7.97 ± 2.03 | < 0.001 | ||||||
| fD*, × 10-3 mm2/s | 0.49± 0.27 vs. 0.94 ± 0.42 | < 0.001 | ||||||
| Togao | Differentiating high-grade gliomas from low-grade gliomas | D, × 10-3 mm2/s | ≤ 1.25 | 100% | 56.2% | 0.78 | ||
| ADC, × 10-3 mm2/s | ≤ 1.29 | 96.6% | 50.0% | 0.73 | ||||
| D*, × 10-3 mm2/s | ≥ 8.43 | 75.9% | 50.0% | 0.60 | ||||
| f (%) | ≥ 7.7 | 96.6% | 81.2% | 0.95 | ||||
| Suh | Glioblastoma group vs. atypical primary central nervous system lymphoma | fmax | reader 1: 0.101 ± 0.016 | reader 1: 89.5% | reader 1: 95.1% | reader 1: < 0.001 | ||
| Liu | Breast malignant tumor | ADC, × 10-3 mm2/s | 0.95 (0.83, 1.06) | 93% | 90% | |||
| D, × 10-3 mm2/s | 0.85 (0.77, 0.98) | 90% | 93% | |||||
| f | 10.34 (7.68, 11.88) | 88% | 54% | |||||
| D*,× 10-3 mm2/s | 94.71 (70.33, 113.23) | 85% | 41% | |||||
| Breast benign lesions | ADC, × 10-3 mm2/s | 1.39 (1.32, 1.50) | 95% | 90% | ||||
| D, × 10-3 mm2/s | 1.99 (1.77, 2.03) | 92% | 96% | |||||
| f | 6.83 (4.72, 10.33) | 89% | 56% | |||||
| D*, × 10-3 mm2/s | 107.49 (83.20, 131.19) | 82% | 44% | |||||
| Breast simple cyst | ADC, × 10-3 mm2/s | 1.96 (1.73, 2.18) | ||||||
| D, × 10-3 mm2/s | 1.35 (1.26, 1.44) | |||||||
| f | 1.69 (0.70, 3.47) | |||||||
| D*, × 10-3 mm2/s | 99.33 (87.04, 155.69) | |||||||
| Valerio | Prostate cancer | ADC, × 10-3 mm2/s | 0.76 ± 0.27 | |||||
| D, × 10-3 mm2/s | 0.99 ± 0.38 | |||||||
| f | 9.35 ± 5.97 | |||||||
| D*, × 10-3 mm2/s | 15.56 ±12.91 | |||||||
| Yamada | HCC | ADC, × 10-3 mm2/s | 1.10 ± 0.18 | |||||
| D, × 10-3 mm2/s | 1.02 ±10.17 | |||||||
| f | 0.15 ±10.07 | |||||||
| D*, × 10-3 mm2/s | ||||||||
| Liver metastasis | ADC, × 10-3 mm2/s | 1.26 ± 0.25 | ||||||
| D, × 10-3 mm2/s | 1.16 ± 0.18 | |||||||
| f | 0.22 ± 0.09 | |||||||
| D*, × 10-3 mm2/s | ||||||||
| Liver hemangioma | ADC, × 10-3 mm2/s | 1.56 ± 0.22 | ||||||
| D, × 10-3 mm2/s | 1.31 ± 0.21 | |||||||
| f | 0.35 ± 0.10 | |||||||
| D*, × 10-3 mm2/s | ||||||||
| Liver cyst | ADC, × 10-3 mm2/s | 3.01 ± 0.28 | ||||||
| D, × 10-3 mm2/s | 3.03 ±0.22 | |||||||
| f | 0.00 ± 0.01 | |||||||
| De Robertis | Pancreatic cancer | ADC, × 10-3 mm2/s | 1.41 (1.02-1.73) | |||||
| D, × 10-3 mm2/s | 1.42 (0.87-1.97) | 77% | 88% | 0.821 | ||||
| f | 5.82 (2.12-18.84) | 91% | 100% | 0.989 | ||||
| D*, × 10-3 mm2/s | 10.23 (1.79-57.85) | 94% | 96% | 0.952 | ||||
| Neuroendocrine neoplasms | ADC, × 10-3 mm2/s | 1.28 (1.01-1.89) | ||||||
| D, × 10-3 mm2/s | 1.2 (0.54-1.56) | |||||||
| f | 27.61 (3.22–80.83) | |||||||
| D*, × 10-3 mm2/s | 28.9 (12.16-73.08) | |||||||
| Autoimmune pancreatitis | ADC, × 10-3 mm2/s | 1.24 (0.94-1.64) | ||||||
| D, × 10-3 mm2/s | 1.16 (0.84-1.76) | |||||||
| f | 9.87 (4.18-11.60) | 100% | 100% | 1.000 | ||||
| D*, × 10-3 mm2/s | 10.62 (7.6-15.15) | 100% | 98% | 0.988 |
ADC - apparent diffusion coefficient; D - diffusion coefficient; D* - pseudodiffusion coefficient; f - perfusion fraction; AUC - area under curve; RCC - renal cell carcinoma; AML- angiomyolipoma; HCC - hepatocellular carcinoma; PP - perfusion-related parameter.